On June 30, 2026, NovoCure announced that its Optune Pax device received a CE Mark for treating adult patients with locally-advanced pancreatic cancer of exocrine origin, used alongside gemcitabine and nab-paclitaxel. The approval includes a reference to guideline recommendations to accommodate regional variations in the use of these chemotherapy agents. NovoCure is a medical device company that develops and commercializes Tumor Treating Fields (TTFields) for the treatment of cancer.
